NO20052276L - Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi - Google Patents
Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapiInfo
- Publication number
- NO20052276L NO20052276L NO20052276A NO20052276A NO20052276L NO 20052276 L NO20052276 L NO 20052276L NO 20052276 A NO20052276 A NO 20052276A NO 20052276 A NO20052276 A NO 20052276A NO 20052276 L NO20052276 L NO 20052276L
- Authority
- NO
- Norway
- Prior art keywords
- gene therapy
- dna molecule
- circulated
- preparation
- replication origin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
- C07K14/501—Fibroblast growth factors [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
En prokaryot rekombinant vertscelle omfattende et heterologt replikasjonsinitieringsprotein som aktiverer et kondisjonalt replikasjonsorigo og et ekstrakromosomalt DNA-molekyl omfattende et heterologt terapeutisk gen og et kondisjonelt replikasjonsorigo der funksjonaliteten i den prokaryote rekombinant vertscelle krever et replikasjonsinitieringsprotein som er fremmed for vertscellen beskrives. Vertscellen kan omfatte et pir-gen med minst en mutasjon, som kan opptre i pir-genkopikontrollområdet, pir-genets gli-delåsliknende leucin motiv eller pir-genets DNA-bindende region.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/268,948 US7279313B2 (en) | 1995-09-15 | 2002-10-11 | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
PCT/US2003/032512 WO2004033664A2 (en) | 2002-10-11 | 2003-10-14 | Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20052276D0 NO20052276D0 (no) | 2005-05-10 |
NO20052276L true NO20052276L (no) | 2005-07-06 |
NO333932B1 NO333932B1 (no) | 2013-10-21 |
Family
ID=32092417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052276A NO333932B1 (no) | 2002-10-11 | 2005-05-10 | Sirkulært DNA-molekyl med betinget replikasjonsorigo samt fremgangsmåte for dets fremstilling. |
Country Status (22)
Country | Link |
---|---|
US (3) | US7279313B2 (no) |
EP (1) | EP1549735B1 (no) |
JP (2) | JP4522861B2 (no) |
KR (1) | KR101323542B1 (no) |
CN (2) | CN101182534B (no) |
AT (1) | ATE521695T1 (no) |
AU (2) | AU2003287078B2 (no) |
BR (1) | BR0314512A (no) |
CA (1) | CA2501851C (no) |
CY (1) | CY1112110T1 (no) |
DK (1) | DK1549735T3 (no) |
ES (1) | ES2372599T3 (no) |
HK (2) | HK1082761B (no) |
IL (1) | IL167706A (no) |
MX (1) | MXPA05003857A (no) |
NO (1) | NO333932B1 (no) |
NZ (2) | NZ539311A (no) |
PT (1) | PT1549735E (no) |
RU (1) | RU2307870C2 (no) |
SI (1) | SI1549735T1 (no) |
WO (1) | WO2004033664A2 (no) |
ZA (1) | ZA200503039B (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7038026B2 (en) * | 2000-05-26 | 2006-05-02 | Centelion | Purification of a triple heli formation with an immobilized oligonucleotide |
FR2738842B1 (fr) * | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
US7279313B2 (en) * | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
FR2822476B1 (fr) * | 2001-03-23 | 2004-04-02 | Aventis Pharma Sa | Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice |
PL1737945T3 (pl) | 2004-04-19 | 2011-07-29 | Aventis Pharma Sa | Sposób oczyszczania plazmidowego DNA |
JP4581851B2 (ja) * | 2004-07-27 | 2010-11-17 | セイコーエプソン株式会社 | 電気光学装置の駆動回路及び駆動方法、電気光学装置並びに電子機器 |
FR2920158B1 (fr) | 2007-08-24 | 2010-03-12 | Centre Nat Rech Scient | Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques |
EP2221066A1 (en) | 2009-02-18 | 2010-08-25 | Sanofi-Aventis | Use of VgII3 activity modulator for the modulation of adipogenesis |
EP2471909A1 (en) * | 2010-12-30 | 2012-07-04 | SIRION BIOTECH GmbH | Nucleic acid molecules for generating adenoviral vectors |
JP5863338B2 (ja) | 2011-08-25 | 2016-02-16 | 株式会社東芝 | プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット |
CA2883227A1 (en) | 2012-08-29 | 2014-03-06 | Nature Technology Corporation | Dna plasmids with improved expression |
US20150322439A1 (en) | 2012-11-19 | 2015-11-12 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
WO2015038958A1 (en) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Selective recovery |
EP3222717B1 (en) * | 2014-11-18 | 2020-04-22 | OriCiro Genomics, Inc. | Method of amplifying circular dna |
EP3808340A1 (en) | 2015-09-18 | 2021-04-21 | Dnarx | Systems and methods for nucleic acid expression in vivo |
WO2017100671A1 (en) * | 2015-12-11 | 2017-06-15 | California Institute Of Technology | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) |
CN110678202B (zh) * | 2017-03-23 | 2023-04-14 | Dnarx公司 | 用于体内核酸表达的系统和方法 |
JP2021518150A (ja) | 2018-03-21 | 2021-08-02 | ネイチャー テクノロジー コーポレーション | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター |
CN112424351A (zh) * | 2018-07-30 | 2021-02-26 | 奥利希罗基因组学有限公司 | 在无细胞体系中对dna进行编辑的方法 |
CN113396221A (zh) * | 2019-01-18 | 2021-09-14 | 詹森生物科技公司 | 作为非抗生素选择标记的β-半乳糖苷酶α肽及其用途 |
WO2023069895A1 (en) * | 2021-10-18 | 2023-04-27 | Modernatx, Inc. | Markerless dna production |
WO2023241567A1 (zh) * | 2022-06-13 | 2023-12-21 | 南京金斯瑞生物科技有限公司 | 一种可提高无筛选标签质粒制备效率的野生型-突变体π蛋白切换表达系统 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4190495A (en) * | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
US4727028A (en) * | 1981-06-22 | 1988-02-23 | Eli Lilly And Company | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof |
US4654307A (en) * | 1983-02-17 | 1987-03-31 | The Research Foundation Of State University Of New York | Novel bacteria containing a plasmid having a tRNA code |
US4761367A (en) * | 1984-11-07 | 1988-08-02 | The University Of North Carolina At Chapel Hill | Vectors suitable for detection of eukaryotic DNA regulatory sequences |
US5859208A (en) * | 1988-07-06 | 1999-01-12 | Fiddes; John C. | Human basic fibroblast growth factor analog |
US5198343A (en) * | 1986-08-05 | 1993-03-30 | Transgene, S.A. | Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained |
US5510099A (en) * | 1987-05-01 | 1996-04-23 | Stratagene | Mutagenesis testing using transgenic non-human animals carrying test DNA sequences |
RU2107725C1 (ru) * | 1989-02-24 | 1998-03-27 | Монсанто Компани | Способ модификации фрагмента днк, кодирующего инсектицидный белок bacillus thuringiensis, фрагмент днк, кодирующий инсектицидный белок bacillus thuringiensis (варианты), фрагмент днк, содержащий структурный ген, кодирующий инсектицидный белок (варианты), и фрагмент днк, содержащий структурный ген, кодирующий слитый белок |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5512463A (en) * | 1991-04-26 | 1996-04-30 | Eli Lilly And Company | Enzymatic inverse polymerase chain reaction library mutagenesis |
TW201794B (no) * | 1991-05-03 | 1993-03-11 | American Cyanamid Co | |
US5714323A (en) * | 1991-08-30 | 1998-02-03 | The University Of Medecine And Dentistry Of New Jersey | Over expression of single-stranded molecules |
US5444149A (en) * | 1992-05-11 | 1995-08-22 | Duke University | Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation |
US5434065A (en) * | 1993-05-06 | 1995-07-18 | President And Fellows Of Harvard College | In vivo selection of microbial virulence genes |
AU7568094A (en) * | 1993-08-12 | 1995-03-14 | Cytotherapeutics, Inc. | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5700657A (en) * | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
IL109558A (en) | 1994-05-04 | 2004-08-31 | Yissum Res Dev Co | DNA structures Derived from the SV40 virus that include DNA sequences External |
JPH10502535A (ja) | 1994-07-08 | 1998-03-10 | シェーリング コーポレイション | c−fosプロモーター活性化タンパク質をコードする核酸を同定する方法 |
DE4428402A1 (de) | 1994-08-11 | 1996-02-15 | Boehringer Mannheim Gmbh | Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen |
US5792647A (en) * | 1995-02-13 | 1998-08-11 | The Johns Hopkins University | Bacterial catabolism of chitin |
US6825012B2 (en) * | 1995-02-23 | 2004-11-30 | Gencell S.A. | DNA molecules, preparation and use in gene therapy |
US6254874B1 (en) * | 1995-04-13 | 2001-07-03 | President And Fellows Of Harvard College | Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same |
JP3530676B2 (ja) * | 1995-04-26 | 2004-05-24 | キヤノン株式会社 | 光受容部材の製造方法、該光受容部材、該光受容部材を有する電子写真装置及び該光受容部材を用いた電子写真プロセス |
US7279313B2 (en) * | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
US7364894B2 (en) * | 1995-09-15 | 2008-04-29 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
FR2738842B1 (fr) * | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
US5851808A (en) | 1997-02-28 | 1998-12-22 | Baylor College Of Medicine | Rapid subcloning using site-specific recombination |
US5874259A (en) | 1997-11-21 | 1999-02-23 | Wisconsin Alumni Research Foundation | Conditionally amplifiable BAC vector |
BRPI0410844A (pt) | 2003-06-05 | 2006-06-27 | Centelion | fator de crescimento de fibroblasto de codificação de plasmìdeo para o tratamento de defeitos angiogênicos associados com hipercolesterolemia ou diabetes |
-
2002
- 2002-10-11 US US10/268,948 patent/US7279313B2/en not_active Expired - Fee Related
-
2003
- 2003-10-14 RU RU2005114367/13A patent/RU2307870C2/ru not_active IP Right Cessation
- 2003-10-14 DK DK03777599.6T patent/DK1549735T3/da active
- 2003-10-14 JP JP2004543780A patent/JP4522861B2/ja not_active Expired - Fee Related
- 2003-10-14 PT PT03777599T patent/PT1549735E/pt unknown
- 2003-10-14 AT AT03777599T patent/ATE521695T1/de active
- 2003-10-14 NZ NZ539311A patent/NZ539311A/en not_active IP Right Cessation
- 2003-10-14 KR KR1020057006228A patent/KR101323542B1/ko not_active IP Right Cessation
- 2003-10-14 MX MXPA05003857A patent/MXPA05003857A/es active IP Right Grant
- 2003-10-14 SI SI200332068T patent/SI1549735T1/sl unknown
- 2003-10-14 BR BR0314512-3A patent/BR0314512A/pt active Search and Examination
- 2003-10-14 CA CA2501851A patent/CA2501851C/en not_active Expired - Fee Related
- 2003-10-14 WO PCT/US2003/032512 patent/WO2004033664A2/en active Application Filing
- 2003-10-14 EP EP03777599A patent/EP1549735B1/en not_active Expired - Lifetime
- 2003-10-14 ES ES03777599T patent/ES2372599T3/es not_active Expired - Lifetime
- 2003-10-14 AU AU2003287078A patent/AU2003287078B2/en not_active Ceased
- 2003-10-14 CN CN2007101620919A patent/CN101182534B/zh not_active Expired - Fee Related
- 2003-10-14 CN CNB2003801041846A patent/CN100491521C/zh not_active Expired - Fee Related
- 2003-10-14 NZ NZ566205A patent/NZ566205A/en not_active IP Right Cessation
-
2005
- 2005-03-28 IL IL167706A patent/IL167706A/en not_active IP Right Cessation
- 2005-04-14 ZA ZA200503039A patent/ZA200503039B/en unknown
- 2005-05-10 NO NO20052276A patent/NO333932B1/no not_active IP Right Cessation
-
2006
- 2006-01-06 HK HK06100304.5A patent/HK1082761B/zh not_active IP Right Cessation
- 2006-05-26 HK HK06106108.0A patent/HK1086297A1/xx not_active IP Right Cessation
- 2006-09-15 US US11/521,412 patent/US7807444B2/en not_active Expired - Fee Related
-
2007
- 2007-10-30 US US11/978,617 patent/US20090252713A1/en not_active Abandoned
-
2009
- 2009-04-09 AU AU2009201405A patent/AU2009201405A1/en not_active Abandoned
- 2009-10-22 JP JP2009243117A patent/JP4750203B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-24 CY CY20111101155T patent/CY1112110T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052276D0 (no) | Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi | |
BRPI0814781A8 (pt) | ''proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico descarboxilase'' | |
Takemoto et al. | Unconventional decoding of the AUA codon as methionine by mitochondrial tRNA Met with the anticodon f 5 CAU as revealed with a mitochondrial in vitro translation system | |
BRPI0516572A (pt) | métodos e composições para melhorar a produção de proteìnas recombinantes | |
NO20081233L (no) | Albumin fusjonsproteiner | |
ATE500331T1 (de) | Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden | |
BR0011499A (pt) | Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado | |
DK1781782T3 (da) | Modificerede vitamin K-afhængige polypeptider | |
PT1685243E (pt) | Linhas celulares aviárias imortalizadas para a produção de vírus | |
AR050299A1 (es) | Plantas con una enzima fosforilante del almidon con una actividad aumentada en plástidos. | |
MA29075B1 (fr) | Enzymes et procedes | |
DK2484758T3 (da) | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet | |
HUP9900018A1 (hu) | Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására | |
BRPI0512798A (pt) | molécula de ácido nucleico recombinante, célula, método para produzir uma proteìna de interesse, uso de uma seqüência de ácido nucleico tendo atividade anti-repressora, métodos para gerar uma célula hospedeira expressando dois polipeptìdios de interesse, e para expressar dois polipeptìdios de interesse | |
ATE278024T1 (de) | Methode zur herstellung von rekombinanten zellen | |
UA95446C2 (ru) | Мутаци в генах oas1 | |
WO2022056254A3 (en) | Dna modifying enzymes and active fragments and variants thereof and methods of use | |
WO2004053137A3 (en) | Method for protein production | |
DE69928395D1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
TW200724679A (en) | Treatment of disease using an improved regulated expression system | |
WO2004005475A3 (en) | Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same | |
WO2006014234A3 (en) | Novel recombinant poxvirus composition and uses thereof | |
ATE373095T1 (de) | Mutierte muskelspezifische enhancer | |
WO2001079525A3 (en) | Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same | |
DE602005018021D1 (de) | Impfstoffe mit ornithobakterium rhinotracheale-untereinheit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |